Glutathione for skin lightening: what the trials show

A tripeptide turned beauty treatment

Glutathione is a tripeptide made of cysteine, glycine and glutamate, synthesized by the body and one of its main antioxidants¹⁵. Its cosmetic use rests on a plausible mechanism: blocking the tyrosinase pathway and shifting melanogenesis toward pheomelanin, a lighter pigment⁶. It is sold in oral, topical and intravenous forms, and its use as a lightening supplement is common in Asia⁴. Dermatologists who have reviewed it describe a phenomenon driven by marketing and especially widespread among people with darker skin¹.

In the region, the intravenous route is usually offered alongside other cosmetic "drips", a market this blog already covered in Law 491, drips and mycobacteria. This article focuses on a different question: what the studies show about skin color.

What the oral and topical trials show

The first randomized, double-blind trial was run in Bangkok with 60 medical students who took 500 mg/day of glutathione or placebo for 4 weeks. The melanin index fell at all six measured sites with glutathione, but the difference versus placebo was significant at only two: the right side of the face (p = 0.021) and the sun-exposed forearm (p = 0.036). Both products were well tolerated, and the authors noted that long-term safety had not been established².

A second trial by the same group compared 250 mg/day of reduced glutathione, 250 mg/day of oxidized glutathione and placebo for 12 weeks in healthy women. Melanin index and UV spots "tended" to be lower with both forms; the reduced form was associated with fewer wrinkles at some sites, with no serious adverse effects³. Topically, a 2% oxidized glutathione lotion applied to half the face for 10 weeks was associated with a lower melanin index than placebo on the other half (p < 0.001) in 30 women; the study was authored by industry researchers¹⁵.

Systematic reviews read these data cautiously. The 2019 review included four studies and concluded that the lightening effect "is still inconclusive", with a trend toward lightening sun-exposed skin and no differences on protected skin⁴. The 2025 review counted five randomized oral trials with significant reductions in melanin index, but rated oral and topical results as moderate and not sustainable over time⁵.

The intravenous drip: a single controlled trial

The best-selling route has the least evidence. According to the 2025 review, there is a single placebo-controlled study of intravenous glutathione: response in 6 of 16 patients (37.5%) vs 3 (18.7%), p = 0.054, not statistically significant; the authors concluded that the intravenous route is contraindicated for this purpose because of lack of efficacy and adverse effects⁵. A 2018 review described that same trial as having a "dubious" design and an apparently flawed analysis¹.

A 2026 narrative review adds a problem of interpretation: intravenous glutathione is usually given together with vitamin C, which makes its independent effect impossible to know. It also mentions signals of hepatotoxicity, hypersensitivity and possible renal and endocrine effects, and concludes that the evidence is too limited to justify routine cosmetic use⁶.

The warnings: the Philippines and the FDA

On 5 July 2019 the Philippine FDA issued Advisory No. 2019-182. It stated that there were no published clinical trials of injectable glutathione for skin lightening and no guidelines on dose or duration, and that in that country injectable glutathione is approved as an adjunct to cisplatin chemotherapy. The risks it listed included liver, kidney and nervous-system toxicity, possible Stevens-Johnson syndrome, kidney stones from the intravenous vitamin C often given with it, hemodialysis after high-dose vitamin C in patients with G6PD deficiency, and transmission of HIV and hepatitis when given in non-sterile settings⁷.

In the United States, the documented problem has been ingredient quality. In February 2019 the FDA warned compounding pharmacies not to use a lot of glutathione powder labeled as a dietary supplement: seven outpatient-clinic patients who received 1,400 mg intravenously developed nausea, vomiting, chills and lightheadedness within minutes, and one was hospitalized⁸. In August 2026 the agency reported at least 30 patients with fever, chills, signs of shock and sepsis-like symptoms after intravenous glutathione compounded from supplement-grade material, consistent with endotoxin exposure⁹. Purity is covered further in What is really in the vial?.

Studied medical uses and a common confusion

Outside aesthetics, parenteral glutathione is registered in some countries for severe liver disease and to prevent chemotherapy neurotoxicity¹. In Parkinson's disease it has been studied with negative results: a pilot trial in 21 patients given 1,400 mg intravenously three times a week for 4 weeks showed no significant differences on the UPDRS scale (2.8 points in favor, p = 0.32)¹⁰; a phase IIb trial in 45 patients using intranasal glutathione for three months was also not superior to placebo, and one participant in the high-dose group developed cardiomyopathy¹¹.

A common confusion in drip advertising is presenting glutathione as "the acetaminophen antidote". The antidote is N-acetylcysteine, which supplies the cysteine the liver needs to make its own glutathione; according to a pharmacology review, its strength is replenishing glutathione in deficient cells, and it is likely ineffective in cells with normal stores¹².

Is it absorbed orally?

The classic doubt was whether oral glutathione survives digestion⁴. The data are mixed. A 4-week trial of 1,000 mg/day in 40 healthy adults found no change in oxidative-stress markers or erythrocyte glutathione¹⁴. By contrast, a 6-month trial in 54 adults showed 30–35% increases in glutathione in erythrocytes, plasma and lymphocytes with the high dose; levels returned to baseline after one month off the supplement¹³.